bs-17744R [Primary Antibody]
MPZL Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: MPZL

Immunogen Range: 61-160/269


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 9019

Swiss Prot: O95297

Source: KLH conjugated synthetic peptide derived from human MPZL

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

MPZL1 is a 269 amino acid widely expressed single-pass type I membrane receptor belonging to the myelin P0 protein family and the immunoglobulin superfamily. MPZL2 (myelin protein zero-like 2), also known as EVA (epithelial V-like antigen) or EVA1, is a 215 amino acid single-pass type I membrane protein that contains one Ig-like V-type (immunoglobulin-like) domain and two potential N-glycosylation sites in its extracellular domain, MPZL2 is expressed in thymus epithelium and is strongly down-regulated by thymocyte developmental progression. MPZL3 (myelin protein zero-like 3) is a 235 amino acid single-pass type I membrane protein that regulates homophilic cell-to-cell adhesion. A member of the myelin P0 protein family, MPZL3 contains one Ig-like V-type (immunoglobulin-like) domain and is expressed in brain, heart, liver and skin. g to the myelin P0 protein family and the immunoglobulin superfamily. Existing as four alternatively spliced isoforms, MPZL1 participates in signal transduction and cell migration.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)

Predicted Molecular Weight: 26


Cross Reactive Species: Mouse

Predicted Cross Reactive Species: Human
Rat
Dog
Cow
Sheep
Horse
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Mouse kidney lysates probed with MPZL Polyclonal Antibody, Unconjugated (bs-17744R) at 1:500 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.